Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):: US48301N1046
LEI:
Country:: United States of America
Address:: 2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Website:: https://kairospharma.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Grifols S.A. Leading producer of plasma-derived medicines for patients with rare and chronic diseases.	Spain	GRF
Grifols SA Develops plasma-derived medicines and transfusion solutions for rare and chronic conditions.	United States of America	GRFS
Grindeks Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.	Latvia	GRD1R
GSK plc Develops specialty medicines and vaccines to prevent and treat a range of global diseases.	United States of America	GSK
GT Biopharma, Inc. Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.	United States of America	GTBP
Guardant Health, Inc. Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.	United States of America	GH
Guard Therapeutics International AB Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.	Sweden	GUARD
GW Vitek CO.,LTD. Develops research antibodies and distributes scientific instruments for life science researchers.	South Korea	036180
GYRE THERAPEUTICS, INC. Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.	United States of America	GYRE
Haleon plc A consumer healthcare leader offering trusted OTC brands for everyday health and wellness.	United States of America	HLN